Untimely Tissue Standards Can Stall Product Development – CBER Rep
This article was originally published in The Gray Sheet
Premature standards development for tissue-engineered medical products (TEMPs) could delay their entry into the market, according to Joyce Frey-Vasconcells, acting deputy director of CBER's Office of Cellular, Tissue & Gene Therapies
You may also be interested in...
Wyeth is reinterpreting clinical data from a 450-patient pivotal study supporting a BMP-2 premarket approval application
The submission of European tissue product premarket filings to a "central expert body" comprising member state representatives is one of various review options explored by the European Commission in a July consultation document
Jakavi joins the likes of Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients